Bruker Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Bruker han disminuido a una tasa media anual de -22.1%, mientras que en la industria Life Sciences los beneficios disminuyeron en un 3.8% anualmente. Los ingresos han ido creciendo a una tasa media de 10.1% al año.
Información clave
-22.06%
Tasa de crecimiento de los beneficios
-21.46%
Tasa de crecimiento del BPA
| Crecimiento de la industria Life Sciences | 21.51% |
| Tasa de crecimiento de los ingresos | 10.12% |
| Rentabilidad financiera | -0.38% |
| Margen neto | -1.05% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • May 14
BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds
Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.
Actualización de narrativa • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.Actualización de narrativa • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.Actualización de narrativa • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Seeking Alpha • Mar 31
Bruker: A Better, Yet Speculative Proposition
Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking AlphaActualización de narrativa • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.Actualización de narrativa • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.Actualización de narrativa • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Artículo de análisis • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...Actualización de narrativa • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.Actualización de narrativa • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.Actualización de narrativa • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.Actualización de narrativa • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.Actualización de narrativa • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Artículo de análisis • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...Actualización de narrativa • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.Actualización de narrativa • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Artículo de análisis • Aug 10
Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...Actualización de narrativa • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Artículo de análisis • Jun 25
Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price
Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...Artículo de análisis • May 31
A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Bruker. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 3,459 | -36 | 960 | 399 |
| 31 Dec 25 | 3,437 | -22 | 944 | 395 |
| 30 Sep 25 | 3,439 | -24 | 946 | 400 |
| 30 Jun 25 | 3,443 | 80 | 933 | 400 |
| 31 Mar 25 | 3,446 | 80 | 923 | 392 |
| 31 Dec 24 | 3,366 | 113 | 893 | 377 |
| 30 Sep 24 | 3,241 | 305 | 853 | 356 |
| 30 Jun 24 | 3,120 | 352 | 802 | 329 |
| 31 Mar 24 | 3,001 | 402 | 763 | 308 |
| 31 Dec 23 | 2,965 | 427 | 730 | 295 |
| 30 Sep 23 | 2,818 | 319 | 687 | 275 |
| 30 Jun 23 | 2,715 | 319 | 644 | 260 |
| 31 Mar 23 | 2,621 | 312 | 625 | 248 |
| 31 Dec 22 | 2,531 | 297 | 608 | 236 |
| 30 Sep 22 | 2,506 | 275 | 598 | 231 |
| 30 Jun 22 | 2,476 | 274 | 605 | 226 |
| 31 Mar 22 | 2,458 | 282 | 577 | 223 |
| 31 Dec 21 | 2,418 | 277 | 563 | 221 |
| 30 Sep 21 | 2,362 | 270 | 544 | 220 |
| 30 Jun 21 | 2,264 | 238 | 518 | 216 |
| 31 Mar 21 | 2,118 | 204 | 485 | 204 |
| 31 Dec 20 | 1,988 | 158 | 472 | 198 |
| 30 Sep 20 | 1,960 | 158 | 470 | 188 |
| 30 Jun 20 | 1,970 | 165 | 480 | 185 |
| 31 Mar 20 | 2,035 | 177 | 503 | 190 |
| 31 Dec 19 | 2,073 | 197 | 500 | 188 |
| 30 Sep 19 | 2,026 | 207 | 491 | 186 |
| 30 Jun 19 | 1,972 | 189 | 473 | 182 |
| 31 Mar 19 | 1,925 | 184 | 459 | 177 |
| 31 Dec 18 | 1,896 | 180 | 449 | 173 |
| 30 Sep 18 | 1,873 | 98 | 443 | 172 |
| 30 Jun 18 | 1,842 | 92 | 440 | 171 |
| 31 Mar 18 | 1,813 | 84 | 432 | 167 |
| 31 Dec 17 | 1,766 | 79 | 420 | 162 |
| 30 Sep 17 | 1,706 | 151 | 407 | 157 |
| 30 Jun 17 | 1,664 | 161 | 399 | 154 |
| 31 Mar 17 | 1,621 | 152 | 396 | 151 |
| 31 Dec 16 | 1,611 | 154 | 394 | 148 |
| 30 Sep 16 | 1,619 | 146 | 393 | 148 |
| 30 Jun 16 | 1,621 | 111 | 393 | 144 |
| 31 Mar 16 | 1,646 | 119 | 390 | 145 |
| 31 Dec 15 | 1,624 | 102 | 392 | 146 |
| 30 Sep 15 | 1,654 | 66 | 408 | 151 |
| 30 Jun 15 | 1,677 | 60 | 420 | 158 |
Ingresos de calidad: BRKR actualmente no es rentable.
Margen de beneficios creciente: BRKR actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: BRKR no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 22.1% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de BRKR en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: BRKR no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Life Sciences (3.8%).
Rentabilidad financiera
Alta ROE: BRKR tiene una rentabilidad financiera negativa (-0.38%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 07:57 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bruker Corporation está cubierta por 29 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |